0NR.F UNIPHAR PLC EO -08
- Market cap
- EUR 1.13B
- P/E
- 20.7x
- P/B
- 2.63x
- ROE
- 12.6%
- Dividend yield
- 0.45%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 0NR.F undervalued?
Graham number0NR.F trades 55.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
UNIPHAR PLC EO -08 fundamental analysis
No fundamental analysis for UNIPHAR PLC EO -08 yet.
UNIPHAR PLC EO -08 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About UNIPHAR PLC EO -08
Uniphar plc, together with its subsidiaries, operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally. It operates through three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail. The company provides sales, marketing, servicing, quality, compliance, regulatory support, and distribution services to medical device manufacturers; high-value services across the life cyc…
Full company profileUNIPHAR PLC EO -08 financial statements
UNIPHAR PLC EO -08 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 1.94B | 2.07B | 2.55B | 2.77B | 3.07B |
| Gross Profit | 274M | 307M | 390M | 428M | 458M |
| Operating Income | 59.5M | 69.6M | 77.7M | 85.1M | 91.4M |
| EBITDA | - | 94.6M | 113M | 137M | 120M |
| Net Income | 48.1M | 45.6M | 44.8M | 64.2M | 51.1M |
| EPS | 0.18 | 0.17 | 0.16 | 0.24 | 0.20 |
| Balance Sheet | |||||
| Total Assets | 945M | 1.11B | 1.29B | 1.42B | 1.73B |
| Total Liabilities | 693M | 821M | 956M | 1.01B | 1.33B |
| Shareholders' Equity | 251M | 290M | 333M | 402M | 405M |
| Cash & Short-term Investments | 78.0M | 104M | 85.7M | 103M | 184M |
| Cash Flow | |||||
| Operating Cash Flow | 52.2M | 82.8M | 52.5M | 124M | 108M |
| Capital Expenditure | 14.4M | 19.9M | 32.0M | 102M | 62.8M |
| Free Cash Flow | 37.7M | 62.9M | 20.6M | 22.2M | 45.6M |
| Ratios | |||||
| ROE | 19.1% | 15.7% | 13.5% | 16.0% | 12.6% |
| ROA | 5.1% | 4.1% | 3.5% | 4.5% | 2.9% |
| Net Profit Margin | 2.5% | 2.2% | 1.8% | 2.3% | 1.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
UNIPHAR PLC EO -08 dividends
- Dividend yield
- 0.45%
- Forward dividend
- 0.02 EUR
- Payout ratio
- 9.9%
- Ex-dividend date
- Sep 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 5.08M | 0.02 | 9.9% |
| 2024 | EUR 5.08M | 0.02 | 7.9% |
| 2023 | EUR 4.83M | 0.02 | 10.8% |
| 2022 | EUR 4.67M | 0.02 | 10.2% |
| 2021 | EUR 5.73M | 0.02 | 11.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns UNIPHAR PLC EO -08
- Insiders 5.52%
- Institutions 51.86%
- Public & others 42.62%
- Shares outstanding 260M
- Free float 239M
UNIPHAR PLC EO -08 company profile
- Company name
- UNIPHAR PLC EO -08
- Ticker
- 0NR.F
- ISIN
- IE00BJ5FQX74
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 3,500
- Fiscal year end
- December
- Address
- 4045 Kingswood Road, Dublin, Ireland, D24 V06K
- Phone
- 353 1 428 7777
- Website
- uniphar.ie
About UNIPHAR PLC EO -08
Uniphar plc, together with its subsidiaries, operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally. It operates through three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail. The company provides sales, marketing, servicing, quality, compliance, regulatory support, and distribution services to medical device manufacturers; high-value services across the life cycle of a pharmaceutical product; and healthcare professionals with access to medicines that cannot source through traditional channels. It is also involved in the pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals and veterinary surgeons; operates a network of pharmacies under the Life, Allcare, Hickey's, and McCauley brands. In addition, the company provides pharmacy support, pharmaceutical supply chain and services, medical device distribution, specialist nursing and infusion, outsourcing and resourcing, healthcare technology, medical affairs, online pharmacy and product fostering, pharmaceutical wholesale distributor, retail pharmacy software and technology, and telecommunications support services, as well as specialist provider of pharmaceuticals. Uniphar plc was founded in 1967 and is headquartered in Dublin, Ireland.
UNIPHAR PLC EO -08 management
9- Mr. Gerard Rabbette B.Comm FCACEO & Executive Director
- Mr. Timothy Dolphin B.Comm FCACFO & Executive Director
- Mr. Allan Smylie C.F.A.Head of Strategy and Investor Relations
- Ms. Aisling McCarthyGeneral Counsel & Company Secretary
- Mr. Seamus EganHead of Corporate Development
- Mr. Brian O'ShaughnessyCCO and Commercial Lead of C&C Pharma & Product Access
- Mr. Dermot RyanManaging Director
- Ms. Kay BonavitaChief Commercial Officer for Uniphar Logistics
- Rick HughesManaging Director of Uniphar Logistics